Avalyn Pharma Inc.

Latest filings

Browse the full filing history (51 filings)

Recent press releases

• Avalyn to Participate in the Jefferies Global Healthcare Conference2026-05-27

  Access to the live webcast of this event, and the archived recording, will be posted under the News & Events page of the Investor section of the company’s website at https://investors.avalynpharma.com/

• Avalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 20262026-05-21

  Updated findings from the ATLAS open-label extension trial will highlight the long-term tolerability profile of AP01 (inhaled pirfenidone) among the cohort of patients with progressive pulmonary fibrosis at up to four years of treatment. See the EULAR online program for more details. The presentation will also be accessible on the company’s website .

• Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference2026-05-05

  “Our presentations at ATS reflect a core belief at Avalyn - that patients should help shape the therapies designed to serve them,” said Lyn Baranowski, CEO of Avalyn Pharma. “By focusing on inhaled approaches and integrating patient and caregiver input early in development, we aim to better understand and improve how therapies are used and experienced in the real-world, not just in clinical trials. We believe this approach is critical to providing the highest care for patients living with pulmonary fibrosis and empowering the pulmonary fibrosis community.”

Similar companies

The largest companies sharing Avalyn Pharma Inc.'s SEC industry classification (pharmaceutical preparations).